Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03ZFG
|
||||
| Former ID |
DAP000659
|
||||
| Drug Name |
Cerulenin
|
||||
| Synonyms |
Helicocerin; Cerulenin, Cephalosporium caerulens; Oxiranecarboxamide, 3-(1-oxo-4,7-nonadienyl)-, (2R-(2-alpha,3-alpha(4E,7E)))-(9CI); (2R,3S)-2,3-Epoxy-4-oxo-7E,10E-dodecadienamide; (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; (2R,3S)-3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; (2R,3S)-3-nona-4,7-dienoyloxirane-2-carboxamide; (2R,3S,E,E)-2,3-Epoxy-4-oxo-7,10-dodecadienamide; (2R-(2alpha,3alpha(4E,7E)))-3-(1-Oxonona-4,7-dienyl)oxirane-2-carboxamide; (2S)(3R)-2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; (2S,3R)-2,3-epoxy-4-oxy-7,10-dodecadienoylamide; (2r,3s)-3-(nona-4,7-dienoyl)oxirane-2-carboxamide; 2,3-Epoxy-4-oxo-7,10-dodecadienamide; 2,3-Epoxy-4-oxo-7,10-dodecadienoylamide; 3-(1-Oxo-4,7-nonadienyl)oxiranecarboxamide; 3-[(4E,7E)-nona-4,7-dienoyl]oxirane-2-carboxamide; 3-nona-4,7-dienoyloxirane-2-carboxamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Dramatic weight loss [ICD9: 783.21; ICD10:R63.4] | Approved | [536472] | ||
| Therapeutic Class |
Antiinfective Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H17NO3
|
||||
| Canonical SMILES |
CC=CCC=CCCC(=O)C1C(O1)C(=O)N
|
||||
| InChI |
1S/C12H17NO3/c1-2-3-4-5-6-7-8-9(14)10-11(16-10)12(13)15/h2-3,5-6,10-11H,4,7-8H2,1H3,(H2,13,15)/b3-2+,6-5+
|
||||
| InChIKey |
GVEZIHKRYBHEFX-ZIMISOLQSA-N
|
||||
| CAS Number |
CAS 17397-89-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Fatty acid synthase | Target Info | Inhibitor | [535387], [537249], [537888] | |
| Pathway Interaction Database | p73 transcription factor network | ||||
| Validated transcriptional targets of deltaNp63 isoforms | |||||
| PathWhiz Pathway | Fatty Acid Biosynthesis | ||||
| WikiPathways | Fatty Acid Biosynthesis | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Liver X Receptor Pathway | |||||
| Activation of Gene Expression by SREBP (SREBF) | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| SREBP signalling | |||||
| Metabolism of water-soluble vitamins and cofactors | |||||
| Integration of energy metabolism | |||||
| Fatty acid, triacylglycerol, and ketone body metabolism | |||||
| AMPK Signaling | |||||
| References | |||||
| Ref 535387 | Proliferation inhibition and apoptosis induction of K562 cells by fatty acid synthase inhibitor--cerulenin. Zhonghua Xue Ye Xue Za Zhi. 2000 May;21(5):244-6. | ||||
| Ref 537249 | Inhibition of Fatty Acid Biosynthesis Prevents Adipocyte Lipotoxicity on Human Osteoblasts In Vitro. J Cell Mol Med. 2009 Mar 27. | ||||
| Ref 537888 | The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev. 1976 Sep;40(3):681-97. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.